MediWound (NASDAQ:MDWD) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of MediWound (NASDAQ:MDWD - Free Report) in a research report released on Monday morning. The brokerage issued an outperform rating and a $34.00 price target on the biopharmaceutical company's stock.

A number of other research firms have also weighed in on MDWD. Alliance Global Partners started coverage on shares of MediWound in a report on Friday, May 2nd. They set a "buy" rating and a $25.00 price target for the company. Craig Hallum initiated coverage on shares of MediWound in a research note on Friday, February 28th. They set a "buy" rating and a $39.00 price objective on the stock. Wall Street Zen upgraded shares of MediWound to a "sell" rating in a research note on Friday, March 21st. Finally, HC Wainwright set a $31.00 price objective on shares of MediWound and gave the company a "buy" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat, MediWound currently has an average rating of "Moderate Buy" and an average target price of $31.80.

MediWound Stock Down 2.9%

Shares of MediWound stock traded down $0.65 during trading hours on Monday, hitting $21.59. The company's stock had a trading volume of 89,683 shares, compared to its average volume of 91,819. MediWound has a 1-year low of $12.78 and a 1-year high of $24.00. The business has a fifty day moving average of $18.00 and a 200 day moving average of $17.82. The company has a market capitalization of $233.34 million, a PE ratio of -7.44 and a beta of 0.30.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.58. The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period last year, the business earned ($1.05) EPS. On average, sell-side analysts anticipate that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. R Squared Ltd bought a new position in shares of MediWound in the 4th quarter worth about $32,000. GAMMA Investing LLC lifted its position in shares of MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 1,162 shares during the last quarter. Corebridge Financial Inc. lifted its position in shares of MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 665 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.